Capo Therapeutics Competitors and Similar CompaniesClear all

Capo Therapeutics's competitors and similar companies include JCR Pharmaceuticals, DiscGenics, Antibe Therapeutics and OTR3.

	Capo Therapeutics Capo Therapeutics is a company that provides vaccine therapies for debilitating diseases of the brain.	JCR Pharmaceuticals JCR Pharmaceuticals is a company that specializes in the development of pharmaceutical products.	DiscGenics DiscGenics is a biopharmaceutical company focused on developing regenerative therapies for patients with diseases of the spine.	Antibe Therapeutics Antibe Therapeutics is a biotechnology company that specializes in the treatment of pain and inflammation.	OTR3 OTR3 is a biotech company that develops therapeutic agents for skin, mucosa, and corneal complications.
Founding Date	Founding Date N/A	Founding Date 1975	Founding Date 2007	Founding Date 2009	Founding Date 2005
Type	Type Private	Type Public	Type Private	Type Public	Type Private
Tags	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development pharma therapy	Tags Healthcare biotech drug development therapy
Locations	Locations HQ	Locations Ashiya, JP HQ Kobe, JP Kobe, JP Kobe, JP Kobe, JP	Locations Salt Lake City, US HQ Salt Lake City, US	Locations Toronto, CA HQ	Locations Paris, FR HQ
Employees	Employees N/A	Employees 934	Employees 363% decrease	Employees 44	Employees 23
Valuation ($)	Valuation ($) N/A	Valuation ($) 533.9 m	Valuation ($) N/A	Valuation ($) 121.9 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ¥33.1b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $7m (FY, 2023)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods ¥8b (FY, 2025)	Cost of goods N/A	Cost of goods $3.9m (FY, 2023)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit ¥25.1b (FY, 2025)	Gross profit N/A	Gross profit $3m (FY, 2023)	Gross profit N/A
Net income	Net income N/A	Net income (¥4.7b) (FY, 2025)	Net income N/A	Net income ($19.5m) (FY, 2023)	Net income N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 68m	Total funding raised $ 6.2m	Total funding raised N/A